WA
AERI

Whitebox Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Whitebox Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-126,130
Closed -$2.42M – 105
2019
Q3 		$2.42M Buy
+126,130
New +$2.89M 0.09% 63

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Whitebox Advisors's AERI Position: Q4 2019 in Review

Whitebox Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2019, closing a stake of 126,130 shares — an estimated $2.42M sold.

Whitebox Advisors first reported a position in AERI in Q3 2019 and held it in 1 quarter. The position peaked at $2.42M in Q3 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q4 2019.

  • Whitebox Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Whitebox Advisors sold 126,130 Aerie Pharmaceuticals shares in Q4 2019, an estimated $2.42M.
  • Whitebox Advisors first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Whitebox Advisors's Aerie Pharmaceuticals position peaked at $2.42M in Q3 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2019.

Based on Whitebox Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.